Information Provided By: 
Fly News Breaks for June 17, 2016
RARE
Jun 17, 2016 | 07:50 EDT
Leerink analyst Joseph Schwartz says Ultragenyx's CEO Emil Kakkis will assume leadership over the ongoing programs on an interim basis following the resignation of the company's chief medical officer, Sunil Agarwal. While the analyst sees the departure as a "new and unexpected" development, he believes execution on Ultragenyx's numerous near-term milestones remains unchanged. Schwartz reiterates an Outperform rating and $85 price target on the shares.
News For RARE From the Last 2 Days
